Business Wire

Slingshot Biosciences Debuts TruCytes™ Potency—Cell Mimics for Scalable, Reproducible CAR-T Potency Assays

EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, the leader in precision-engineered cell mimic technologies, today announced the launch of TruCytes™ Potency, a new class of biomarker cell ...
Morningstar

Slingshot Biosciences Launches TruCytes™ Potency CD20 & CD34 Stem Cell Gating Controls, Standardizing Critical Readouts While Slashing Variability, Time, and Cost

Slingshot Biosciences (“Slingshot”) today announced two additions to its TruCytes™ cell mimic product line designed to accelerate cell therapy and stem cell research, development, and manufacturing ...
BioWorld

Tscan’s TCR T-cell therapy demonstrates specificity and potency in preclinical models

Researchers from Tscan Therapeutics Inc. presented preclinical data for TSC-200-A0201, a naturally occurring HPV16 E7-specific T-cell receptor (TCR) T-cell therapy discovered using Tscan’s proprietary ...